A Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplant.
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Renal Disorder
Intervention: MK0954, losartan potassium/Duration of Treatment: 2 years (Drug); Comparator: placebo / Duration of Treatment: 2 years (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
A study to determine the renal protective effect (measured as an incidence of chronic
allograft nephropathy)of losartan in patients after renal transplant.
Clinical Details
Official title: Extension Study Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of Losartan in Patients With Renal Transplants
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Number of patients who experience histological lesions of chronic allograft nephropathy
Secondary outcome: Cardiovascular morbidity and mortality, plasma levels of creatinine, proteinuria, safety and tolerability
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females at least 18 years of age who have undergone a renal transplant.
Locations and Contacts
Merck Sharp & Dohme De Espana, S.A.E., Madrid 28027, Spain
Additional Information
Starting date: April 2000
Last updated: October 25, 2005
|
